Mirogabalin besilate

苯磺酸美洛加巴林

Report date: 2025/11/21 16:13:52
NME

Base Information

Drug NameMirogabalin besilate
Drug Alias Namemirogabalina美洛加巴林mirogabaline米洛巴林mirogabalinum +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 1 blockers
TargetsVoltage-gated calcium channel alpha2/delta subunit 1
Therapy Area/IndicationsDiabetic peripheral neuropathyPainNeuralgia, Postherpetic +[7] 
Global Approved IndicationsNeuralgia, PostherpeticDiabetic NeuropathiesPeripheral Nervous System Diseases
Approved Indications in ChinaDiabetic Neuropathies
Original Approved Country/TerritoryJapan
Original Approved Date2019/01/08
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo Co Ltd
Inactive CompaniesDaiichi Sankyo (China) Holdings Co LtdTakatsuki Plant Taiyo Pharma Tech Co LtdFountain (Beijing) Pharmaceutical Technology Development Co Ltd
Active IndicationsNeuralgia, PostherpeticNeuralgiaDiabetic Neuropathies +[4] 
Inactive IndicationsDiabetic peripheral neuropathyPainFibromyalgia

Other Information

ATC CodeN
Related LinksWikipediaKEGG